Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

Pharmacology and Therapeutics

Volumn 133, Issue 1, 2012, Pages 116-123

  Griebel, Guy ^a   Beeské, Sandra ^a  

^a SANOFI   (France)

Author keywords

Anxiety disorders; Major depressive disorder; Neurokinin 3 receptor; Neuropeptide; Schizophrenia; Tachykinin

Indexed keywords

AMITRIPTYLINE; AZD 2624; DESIPRAMINE; FLUOXETINE; GSK 256471; HALOPERIDOL; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROKININ A [4-10][7 TRYPTOPHAN 8 BETA ALANINE]; NEUROKININ B; OLANZAPINE; OSANETANT; RISPERIDONE; SB 235375; SENKTIDE; SSR 146977; TALNETANT; UNCLASSIFIED DRUG;

ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; DEPRESSION; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HUMAN; MENTAL DISEASE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 83555172615     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.09.007     Document Type: Review

References (91)

1. T.A. Almeida, J. Rojo, P.M. Nieto, F.M. Pinto, M. Hernandez, and J.D. Martin Tachykinins and tachykinin receptors: Structure and activity relationships Curr Med Chem 11 2004 2045 2081
2. R. Alonso, M. Fournier, P. Carayon, G. Petitpretre, G. Le Fur, and P. Soubrié Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures Eur J Neurosci 8 1996 801 808
3. M.J. Bannon, L.A. Brownschidle, Y. Tian, C.J. Whitty, M.S. Poosch, and C. D'sa Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine Brain Res 695 1995 19 24
4. 1 receptor-mediated activation of the locus coeruleus revealed by SR 142801 Synapse 43 2002 62 69
5. J.R. Boissier, P. Simon, and C. Aron A new method for the rapid screening of minor tranquilisers in mice Eur J Pharmacol 4 1968 145 151
6. T.I. Bonner, H.U. Affolter, A.C. Young, and W.S. Young III A cDNA encoding the precursor of the rat neuropeptide, neurokinin B Brain Res 388 1987 243 249
7. J.D. Bremner, J.H. Krystal, S.M. Southwick, and D.S. Charney Noradrenergic mechanisms in stress and anxiety. 1. Preclinical studies Synapse 23 1996 28 38
8. J.D. Bremner, J.H. Krystal, S.M. Southwick, and D.S. Charney Noradrenergic mechanisms in stress and anxiety. 2. Clinical studies Synapse 23 1996 39 51
9. S.H. Buck, C.J. Helke, E. Burcher, C.W. Shults, and T.L. O'Donohue Pharmacologic characterization and autoradiographic distribution of binding sites for iodinated tachykinins in the rat central nervous system Peptides 7 1986 1109 1120
10. C. Carpentier, and A. Baude Immunocytochemical localisation of NK3 receptors in the dorsal vagal complex of rat Brain Res 734 1996 327 331
11. M.S. Carter, and J.E. Krause Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma J Neurosci 10 1990 2203 2214
12. L.W. Chen, Z.L. Guan, and Y.Q. Ding Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): A double immunocytochemical study in the rat Brain Res 780 1998 150 154
13. R. Ciccocioppo, I. Panocka, C. Polidori, G. de Caro, D. Regoli, and M. Massi Stimulation of tachykinin NK-3 receptors in the nucleus basalis magnocellularis reduces alcohol intake in rats Peptides 18 1997 1349 1355
14. R. Ciccocioppo, I. Panocka, C. Polidori, R. Froldi, S. Angeletti, and M. Massi Mechanism of action for reduction of ethanol intake in rats by the tachykinin NK-3 receptor agonist aminosenktide Pharmacol Biochem Behav 61 1998 459 464
15. R. Ciccocioppo, I. Panocka, P. Pompei, G. de Caro, and M. Massi Selective agonists at NK3 tachykinin receptors inhibit alcohol intake in Sardinian alcohol-preferring rats Brain Res Bull 33 1994 71 77
16. R. Ciccocioppo, I. Panocka, P. Pompei, C. Polidori, G. de Caro, and M. Massi Subcutaneous injections of the tachykinin senktide reduce alcohol intake in alcohol-preferring rats Peptides 16 1995 533 537
17. L.J. Dableh, K. Yashpal, J. Rochford, and J.L. Henry Therapeutic potential of NK-1, -2 and -3 receptor inhibition in an animal model of depression Program No 307 4 Abstract Viewer/Itinerary Planner 2002 Society for Neuroscience Washington, DC CD-ROM
18. 3H]senktide Brain Res 506 1990 175 179
19. L.A. Dawson, C.J. Langmead, A. Dada, J.M. Watson, Z. Wu, and F.R. de la In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics Eur J Pharmacol 627 2010 106 114
20. L.A. Dawson, and P.W. Smith Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia Curr Pharm Des 16 2010 344 357
21. R. de la Flor, and L.A. Dawson Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412) Neuropharmacology 56 2009 342 349
22. T.C.M. De Lima, R.M. Teixeira, A.R.S. Santos, G.A. Rae, and J.B. Calixto Behavioral effects of intracerebroventricular injection of selective tachykinin agonists and antagonists Soc Neurosci Abstr 21 1995 1696
23. M.A. De Souza Silva, E.L. Mello Jr., C.P. Muller, G. Jocham, R.S. Maior, and J.P. Huston The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys Eur J Pharmacol 536 2006 269 278
24. Y.Q. Ding, R. Shigemoto, M. Takada, H. Ohishi, S. Nakanishi, and N. Mizuno Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat J Comp Neurol 364 1996 290 310
25. K. Ebner, S.B. Sartori, and N. Singewald Tachykinin receptors as therapeutic targets in stress-related disorders Curr Pharm Des 15 2009 1647 1674
26. P.J. Elliott, G.S. Mason, M. Stephens-Smith, and R.M. Hagan Behavioural and biochemical responses following activation of midbrain dopamine pathways by receptor selective neurokinin agonists Neuropeptides 19 1991 119 126
27. X. Emonds-Alt, D. Bichon, J.P. Ducoux, M. Heaulme, B. Miloux, and M. Poncelet SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor Life Sci 56 1995 L27 L32
28. X. Emonds-Alt, V. Proietto, R. Steinberg, C. Advenier, S. Daoui, and E. Naline Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist Can J Physiol Pharmacol 80 2002 482 488
29. 2) receptor Life Sci 50 1992 PL-101 PL-106
30. S. Evangelista Talnetant GlaxoSmithKline Curr Opin Investig Drugs 6 2005 717 721
31. S.E. File, S. Cheeta, and C. Akanezi Diazepam and nicotine increase social interaction in gerbils: A test for anxiolytic action Brain Res 888 2001 311 313
32. T. Foroud, L.F. Wetherill, J. Kramer, J.A. Tischfield, J.I. Nurnberger Jr., and M.A. Schuckit The tachykinin receptor 3 is associated with alcohol and cocaine dependence Alcohol Clin Exp Res 32 2008 1023 1030
33. G. Griebel 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research Pharmacol Ther 65 1995 319 395
34. G. Griebel Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82 1999 1 61
35. G. Griebel, G. Perrault, and P. Soubrie Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents Psychopharmacology 158 2001 241 251
36. C. Gueudet, V. Santucci, P. Soubrie, and G. Le Fur Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs Synapse 33 1999 71 79
37. D.W. Hay, G.A. Giardina, D.E. Griswold, D.C. Underwood, C.J. Kotzer, and B. Bush Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs J Pharmacol Exp Ther 300 2002 314 323
38. C.J. Helke, J.E. Krause, P.W. Mantyh, R. Couture, and M.J. Bannon Diversity in mammalian tachykinin peptidergic neurons: Multiple peptides, receptors, and regulatory mechanisms FASEB J 4 1990 1606 1615
39. C. Humpel, and A. Saria Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat Neurosci Lett 157 1993 223 226
40. C. Humpel, A. Saria, and D. Regoli Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism Eur J Pharmacol 195 1991 107 114
41. 3 receptor antagonists Bioorg Med Chem Lett 21 2011 1498 1501
42. M. Jung, J.C. Michaud, R. Steinberg, M.C. Barnouin, A. Hayar, and G. Mons Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation Neuroscience 74 1996 403 414
43. K.D. Keegan, G.N. Woodruff, and R.D. Pinnock The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro Br J Pharmacol 105 1992 3 5
44. G.F. Koob Corticotropin-releasing factor, norepinephrine, and stress Biol Psychiatry 46 1999 1167 1180
45. G. Kronenberg, P. Berger, R.F. Tauber, B. Bandelow, V. Henkel, and I. Heuser Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges Pharmacopsychiatry 38 2005 24 29
46. X. Langlois, C. Wintmolders, R.P. te, J.E. Leysen, and M. Jurzak Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: A comparative autoradiographic study Neuropharmacology 40 2001 242 253
47. A. Lessard, M. Savard, F. Gobeil Jr., J.P. Pierce, and V.M. Pickel The neurokinin-3 (NK3) and the neurokinin-1 (NK1) receptors are differentially targeted to mesocortical and mesolimbic projection neurons and to neuronal nuclei in the rat ventral tegmental area Synapse 63 2009 484 501
48. M. Liem-Moolenaar, F. Gray, V.S. de, K. Franson, R. Schoemaker, and J. Schmitt Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol J Psychopharmacol 2008
49. U. Liminga, P.E. Johansson, and L. Gunne Intranigral tachykinin NK3 receptor agonist elicits oral movements in rats Pharmacol Biochem Behav 38 1991 617 620
50. C.A. Maggi The mammalian tachykinin receptors Gen Pharmacol 26 1995 911 944
51. P. Malherbe, T.M. Ballard, and H. Ratni Tachykinin neurokinin 3 receptor antagonists: A patent review (2005-2010) Expert Opin Ther Pat 21 2011 637 655
52. 3 receptors Br J Pharmacol 162 2011 929 946
53. J. Man, M. Jurzak, and T. Stohr The NK3 receptor antagonist SR142801 reverses apomorphine-induced deficits on prepulse inhibition in gerbils Behav Pharmacol 11 2000 343
54. 3 receptor stimulation: An in vivo microdialysis approach in guinea pig Neuropeptides 32 1998 481 488
55. M. Massi, I. Panocka, and G. de Caro The psychopharmacology of tachykinin NK-3 receptors in laboratory animals Peptides 21 2000 1597 1609
56. A.D. Medhurst, A.A. Parsons, J.C. Roberts, and D.W. Hay Characterization of NK3 receptors in rabbit isolated iris sphincter muscle Br J Pharmacol 120 1997 93 101
57. H.Y. Meltzer, L. Arvanitis, D. Bauer, and W. Rein Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder Am J Psychiatry 161 2004 975 984
58. M. Munoz, and R. Covenas NK-1 receptor antagonists: A new paradigm in pharmacological therapy Curr Med Chem 18 2011 1820 1831
59. 125I]-Bolton-Hunter scyliorhinin II: A novel, selective radioligand for the tachykinin NK3 receptor in rat brain Peptides 11 1990 827 836
60. E. Nalivaiko, J.C. Michaud, P. Soubrie, G. Le Fur, and P. Feltz Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: An in vitro electrophysiological study Neuroscience 78 1997 745 757
61. Q.T. Nguyen, D. Jukic, L. Chretien, F. Gobeil, M. Boussougou, and D. Regoli Two NK-3 receptor subtypes: Demonstration by biological and binding assays Neuropeptides 27 1994 157 161
62. R.E. Nordquist, T.M. Ballard, B. Algeyer, M. Pauly-Evers, L. Ozmen, and W. Spooren Pharmacological characterization of senktide-induced tail whips Neuropharmacology 58 2010 259 267
63. C.A. Nwaneshiudu, and E.M. Unterwald Blockade of neurokinin-3 receptors modulates dopamine-mediated behavioral hyperactivity Neuropharmacology 57 2009 295 301
64. M. Otsuka, and K. Yoshioka Neurotransmitter functions of mammalian tachykinins Physiol Rev 73 1993 229 308
65. F. Oury-Donat, P. Carayon, O. Thurneyssen, V. Pailhon, X. Emonds-Alt, and P. Soubrie Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells J Pharmacol Exp Ther 274 1995 148 154
66. P. Overton, P.J. Elliott, R.M. Hagan, and D. Clark Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat Eur J Pharmacol 213 1992 165 166
67. I. Panocka, R. Ciccocioppo, C. Polidori, S. Angeletti, G. de Caro, and M. Massi Sensitivity of brain sites to the inhibitory effect on alcohol intake of the tachykinin aminosenktide Peptides 19 1998 897 905
68. I. Panocka, M. Massi, I. Lapo, T. Swiderski, M. Kowalczyk, and B. Sadowski Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity Peptides 22 2001 1037 1042
69. M. Perfumi, C. Polidori, P.L. Pompei, G. de Caro, and M. Massi The tachykinin NH2-senktide inhibits alcohol intake in alcohol- preferring rats Pharmacol Biochem Behav 38 1991 881 887
70. F.M. Pinto, T.A. Almeida, M. Hernandez, P. Devillier, C. Advenier, and M.L. Candenas mRNA expression of tachykinins and tachykinin receptors in different human tissues Eur J Pharmacol 494 2004 233 239
71. L. Quartara, M. Altamura, S. Evangelista, and C.A. Maggi Tachykinin receptor antagonists in clinical trials Expert Opin Investig Drugs 18 2009 1843 1864
72. R.L. Ribeiro, and T.C.M. De Lima Participation of GABA(A) receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice Prog Neuropsychopharmacol Biol Psychiatry 26 2002 861 869
73. S.J. Ribeiro, and T.C.M. DeLima Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice Neurosci Lett 258 1998 155 158
74. S.J. Ribeiro, R.M. Teixeira, J.B. Calixto, and T.C.M. DeLima Tachykinin NK3 receptor involvement in anxiety Neuropeptides 33 1999 181 188
75. N.M.J. Rupniak, E.J. Carlson, J.K. Webb, T. Harrison, R.D. Porsolt, and S. Roux Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs Behav Pharmacol 12 2001 497 508
76. M. Saffroy, Y. Torrens, J. Glowinski, and J.C. Beaujouan Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: Comparison with NK1 and NK3 binding sites Neuroscience 116 2003 761 773
77. N. Salome, J. Stemmelin, C. Cohen, and G. Griebel Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils Pharmacol Biochem Behav 83 2006 533 539
78. H.M. Sarau, D.E. Griswold, B. Bush, W. Potts, P. Sandhu, and D. Lundberg Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist J Pharmacol Exp Ther 295 2000 373 381
79. H.M. Sarau, D.E. Griswold, W. Potts, J.J. Foley, D.B. Schmidt, and E.F. Webb Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist J Pharmacol Exp Ther 281 1997 1303 1311
80. G.R. Seabrook, B.J. Bowery, and R.G. Hill Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices Eur J Pharmacol 273 1995 113 119
81. P.J. Shughrue, M.V. Lane, and I. Merchenthaler In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system J Comp Neurol 372 1996 395 414
82. 3 receptor antagonists for the treatment of schizophrenia and other CNS indications Curr Opin Drug Discov Devel 13 2010 379 388
83. P.W. Smith, P.A. Wyman, P. Lovell, C. Goodacre, H.T. Serafinowska, and A. Vong New quinoline NK3 receptor antagonists with CNS activity Bioorg Med Chem Lett 19 2009 837 840
84. W. Spooren, C. Riemer, and H. Meltzer Opinion: NK3 receptor antagonists: The next generation of antipsychotics? Nat Rev Drug Discov 4 2005 967 975
85. A.J. Stoessl, C.T. Dourish, S.C. Young, B.J. Williams, S.D. Iversen, and L.L. Iversen Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse Neurosci Lett 80 1987 321 326
86. 3H]senktide Brain Res 534 1990 1 7
87. A.J. Stoessl, E. Szczutkowski, B. Glenn, and I. Watson Behavioural effects of selective tachykinin agonists in midbrain dopamine regions Brain Res 565 1991 254 262
88. N. Suman-Chauhan, P. Grimson, S. Guard, Z. Madden, F.Z. Chung, and K. Watling Characterisation of [125I][MePhe7]neurokinin B binding to tachykinin NK3 receptors: Evidence for interspecies variance Eur J Pharmacol 269 1994 65 72
89. M. Sundqvist, E. Kristensson, R. Adolfsson, A. Leffler, I. Ahlstedt, and S. Engberg Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists Eur J Pharmacol 577 2007 78 86
90. J.A. Van der Heyden, and L.D. Bradford A rapidly acquired one-way conditioned avoidance procedure in rats as a primary screening test for antipsychotics: Influence of shock intensity on avoidance performance Behav Brain Res 31 1988 61 67
91. J. Yip, and L.A. Chahl Localization of NK1 and NK3 receptors in guinea-pig brain Regul Pept 98 2001 55 62